CORE--DNA DIAGNOSTIC LABORATORY AND WEST BAY COMPONENTS--HEMOGLOBINOPATHY LAB
CORE--DNA DIAGNOSTIC LABORATORY AND WEST BAY COMPONENTS--HEMOGLOBINOPATHY LAB
批准号:
6241648
负责人:
Stephen H. Embury
金额:
$26.88万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-04-01 至 1998-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The DNA diagnostic laboratory at San Francisco General Hospital is
requesting continued funding as a Core laboratory that will provide DNA-
based genotypic diagnoses for the Northern California Comprehensive
Sickle Cell Center and serve as a diagnostic resource for other
institutions. We will provide genotypic diagnoses for subjects in
studies at the center and for patients whose clinical diagnosis cannot
be determined readily using standard clinical testing, and will continue
to develop improved methods for DNA diagnosis. Specifically, we will
determine betas-globin and alpha-globin genotypes and beta-RFLP
haplotypes of subjects to be enrolled in clinical and basic science
studies at the Northern California Comprehensive Sickle Cell Center,
which will be correlated with the information obtained in those studies.
We will also provide genotype diagnoses for patients having difficult-to-
diagnose hemoglobinopathies, including those for whom original diagnosis
were not obtained before they were begun on chronic transfusion therapy,
candidates for prenatal diagnosis whose mutations must be defined at the
DNA level before prenatal diagnosis can be undertaken, and patients whose
genotype diagnoses are obscured by complex interactions of multiple
hemoglobinopathic genes. We will also continue to develop and adapt
methods that offer advantages for DNA based diagnosis in sickle cell
disease and other hemoglobinopathies. Methods that we are currently
developing in our laboratory include direct sequence analysis of PCR
product, denaturing gradient gel electrophoresis, single strand
confirmational polymorphism, and gap PCR. These methods will provide
greater breadth of diagnostic capabilities in our laboratory and may
offer potential for replacing certain of the diagnostic method we
currently employ. The availability of the sophisticated diagnostic
methods used in this laboratory will complement and supplement the
diagnostic abilities of the Core Hemoglobinopathy Laboratory.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy
-
批准号:9202918
-
项目类别:
-
资助金额:$166.82万
-
财政年份:2014
-
负责人:Stephen H. Embury
-
依托单位:
Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy
-
批准号:8780313
-
项目类别:
-
资助金额:$22.6万
-
财政年份:2014
-
负责人:Stephen H. Embury
-
依托单位:
Reliable Assays for Pentosan Polysulfate Sodium
-
批准号:8648586
-
项目类别:
-
资助金额:$22.64万
-
财政年份:2014
-
负责人:Stephen H. Embury
-
依托单位:
ACTIVATED ENDOTHELIAL ADHESIVITY IN SC VASOOCCLUSION
-
批准号:6617851
-
项目类别:
-
资助金额:$31.97万
-
财政年份:2000
-
负责人:Stephen H. Embury
-
依托单位:
ACTIVATED ENDOTHELIAL ADHESIVITY IN SC VASOOCCLUSION
-
批准号:6062396
-
项目类别:
-
资助金额:$31.9万
-
财政年份:2000
-
负责人:Stephen H. Embury
-
依托单位:
ACTIVATED ENDOTHELIAL ADHESIVITY IN SC VASOOCCLUSION
-
批准号:6390650
-
项目类别:
-
资助金额:$30.11万
-
财政年份:2000
-
负责人:Stephen H. Embury
-
依托单位:
ACTIVATED ENDOTHELIAL ADHESIVITY IN SC VASOOCCLUSION
-
批准号:6527377
-
项目类别:
-
资助金额:$31.04万
-
财政年份:2000
-
负责人:Stephen H. Embury
-
依托单位:
ENDOTHELIAL CELL REACTIVITY IN SICKLE CELL VASOOCCLUSION
-
批准号:6325901
-
项目类别:
-
资助金额:$23.29万
-
财政年份:2000
-
负责人:Stephen H. Embury
-
依托单位:
ENDOTHELIAL CELL REACTIVITY IN SICKLE CELL VASOOCCLUSION
-
批准号:6109522
-
项目类别:
-
资助金额:$23.29万
-
财政年份:1999
-
负责人:Stephen H. Embury
-
依托单位:
ENDOTHELIAL CELL REACTIVITY IN SICKLE CELL VASOOCCLUSION
-
批准号:6272592
-
项目类别:
-
资助金额:$23.56万
-
财政年份:1998
-
负责人:Stephen H. Embury
-
依托单位:
CORE--DNA DIAGNOSTIC LABORATORY AND WEST BAY COMPONENTS--HEMOGLOBINOPATHY LAB
-
批准号:5213306
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Stephen H. Embury
-
依托单位:--
海外基金